摘要
肥胖在未來將會是最嚴重醫療問題之一。勞工朋友中有體重過重困擾的不在少數，肥胖和高血壓、糖尿病、高血脂、骨質疏鬆等重大疾病者有密不可分之關連性。很多勞工朋友會自行購買減肥藥服用。而幾年前很多愛美女士購買減肥藥，造成多例因肺部纖維死亡之案例。很多減肥藥物結構類似甲狀腺素及安非他命，有些以輕溶劑混充，造成很多副作用，希望勞工朋友服用任何藥物，一定要經過醫師處方。當然近日讓你酷受到各界矚目，本文回顧相關資訊，提供各位醫師做參考。未來此藥若引進台灣，可做為依循，當然減肥首要之原則「少吃多動」，如果僅靠藥物，絕不可能達成目的。
關鍵字
肥胖並列摘要
Administration is orlistat (Xenical), a pancreatic lipase inhibitor that reduces the absorption of dietary fat by approximately 30%, thus reducing energy intake. In a 1-year placebo-controlled trial, 55% of patients receiving orlistat lost more than 5% of their body weight, and 25% lost more than 10% of their body weight, compared with 33% and 15%, respectively, of patients in the placebo group. in addition, orlistat slowed the rate of weight regain in the second year of treatment. Health benefits demonstrated in clinical trials of orlistat include reduced LDL cholesterol levels and increased levels of HDL cholesterol, reduced blood pressure and fasting insulin levels, improved oral glucose tolerance test outcomes, and improved glycemic control in obese patients with diabetes. The future of the pharmacologic treatment of obesity is promising. Many new antiobesity agents are in the early stages of development, and our understanding of the body’s weight-regulating mechanisms is advancing steadily. Human trials of recombinant leptin are underway. Other promising compounds include those that block the Neuropeptide Y5 and Y1 (NY5, NY1) and Melanocortin-4 (MC4) receptors, stimulate uncoupling proteins, and unbind corticotrophin-releasing factor from its binding protein. As better medical treatments for obesity become available, the focus in dietary prescription may shift away from reducing energy intake toward healthier eating for disease prevention. At present, a comprehensive approach, which in some patients, may include medical therapy as an adjunct, is necessary to treat obesity effectively.